小檗碱联合阿托伐他汀治疗对急性冠脉综合征患者循环内皮祖细胞的影响

Effects of Berberine and Atorvastatin on Circulating Endothelial Progenitor Cells in Patients with Acute Coronary Syndrome

目的观察小檗碱联合小剂量阿托伐他汀对急性冠脉综合征(ACS)患者血脂、高敏C反应蛋白(hsCRP)和外周血循环内皮祖细胞(cEPC)的影响。方法将120例ACS患者随机分为对照组和观察组,每组60例。对照组给予阿托伐他汀40mg,每日1次,阿托伐他汀20mg,每日1次,观察组给予小檗碱300mg,每日3次,阿托伐他汀20mg,每日1次,随访3个月。分析两组患者血脂、hsCRP和cEPC变化,观察丙氨酸氨基转移酶(ALT)、肌酸激酶(CK)水平变化及各种不良事件发生情况。结果与对照组相比,观察组在1个月和3个月血脂、hsCRP和外周血cEPC水平差异无统计学意义,1个月时ALT降低更明显(P<0.05),CK和不良事件发生率相似。结论小檗碱联合小剂量阿托伐他汀具有与大剂量阿托伐他汀相似的调脂、抗炎、促cEPC效应和安全性,对肝功能影响更小。

Objective To observe the effects of berberine plus low dose atorvastatin on lipids profile, high - sensitivity C - reactive protein （hsCRP） and peripheral blood circulating endothelial progenitor cells （cEPCs） in patients with acute coronary syndrome （ACS）. Methods One hundred and twenty patients with ACS were randomly divided into two groups：The control group （n=60） re- ceived atorvastatin 40 mg qd,and the observation group （n=60） treated with berberine 300 mg tid plus atorvastatin 20 mg qd. One month later, all patients received atorvastatin 20 mg qd and followed up for 3 months. Lipids, hsCRP, cEPCs, alanine aminotransferase （ALT） and creatine kinase （CK） were analyzed in two groups chronologically, and major adverse events （MAE） were recorded. Re- suits There was no significant difference in blood lipid, hsCRP, CK, cEPCs and MAE between two groups. Comparing to control group, ALT was lower in observation group after 1 month combination therapy （P〈0.05）. Conclusion Berberine plus low dose atorvastatin had similar effects on lipids- regulation, anti- inflammatory, and motivating cEPCs as high dose statin did.